CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...